Biotech Values

[biotech jim]

Looks to me that they are doing a large peripheral blood biomarker survey for complement factor component levels and activation as predictors of responding patients with this factor D blocking antibody, lampalizumab or TNX-234. Probably need this type of data to prove that this is a winner and to make this approvable. Not certain that peripheral blood markers predict what is going on intra-ocularly though. Is this level of efficacy seen (20.4% reduction in GA) clinically meaningful?

I wondered what happened to this program, as the complement factor pathway has been strongly implicated in a variety of inflammatory situations including dry AMD. Took a while for this program to see the light of day, as long trials are needed for determining efficacy. Thanks for posting this.